Real-world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non-interventional study in China

[摘要] Ovarian cancer remains the deadliest among all gynecological cancers. Although most patients at advancedstage respond to initial treatment, the majority experience recurrence [1]. It was estimated that 55,342 newcases and 37,519 deaths from ovarian cancer occurred inChina annually [2]. Contemporarily, the treatment landscape has changed rapidly since the role of poly(adenosinediphosphate-ribose) polymerase inhibitors (PARPi) inovarian cancer treatment was explored. Based on data fromthe PRIMA/ENGOT-OV26/GOG-3012 [3] and ENGOTOV16/NOVA trials [4], niraparib has been approved globally as maintenance therapy for newly diagnosed andplatinum-sensitive recurrent ovarian cancer. The indication of niraparib for salvage treatment was based on theresults of the QUADRA (NCT02354586) trial [5]. Althoughniraparib has been tested in prospective randomized clinical trials (RCTs), no multicenter study on its real-worldapplication in China had been conducted. Considering thedifferences in population, accessibility and affordability ofdrugs, the results of the real-world settings may differ fromthose of RCTs. Therefore, we conducted this multicenter,non-interventional study at 8 hospitals.

[学科分类] 社会科学、人文和艺术（综合）